T1124

Flumethasone (RS-2177) is a glucocorticoid receptor agonist, with anti-inflammatory, antipruritic and vasoconstrictive properties.

Dxd (OQM5SD32BQ) is a potent DNA topoisomerase I inhibitor (IC50= 0.31 μM). Dxd was used as a conjugate drug for HER2-targeted ADCs.

Exatecan (DX-8951f) is a DNA topoisomerase I (TOP1) inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL).Exatecan has antitumor activity and may be used in cancer research.

Ethacrynic acid, a diuretic, functions as an inhibitor of L-type voltage-dependent and store-operated calcium channels, facilitating the relaxation of airway smooth muscle (ASM) cells. It exhibits anti-inflammatory effects, notably reducing retinoid-induced ear edema in mice, and inhibits glutathione S-transferases (GSTs), making it a potent suppressor of the NF-kB signaling pathway. Additionally, ethacrynic acid modulates leukotriene formation. A variant, Ethacrynic acid-D5, is distinguished by its deuterium labeling.

p38 MAPK-IN-2 is a potent inhibitor of p38 kinase.

Ethyl glucuronide (Ethyl-β-D-glucuronide) is a non-oxidized ethanol metabolite that is a biomarker for chronic alcohol consumption.

Gliclazide is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Ethyl tosylcarbamate is an intermediate in the synthesis of Gliclazide (G409877).

Etimizol (Ethimizole) was shown to relieve amnesia effectively in the origin of which there is the hypoxic component (hypobaric hypoxia, actinomycin D, mechanical injury of the brain). The positive effect of Etimizol on memory is related to its influence on the consolidation stage.

Etoricoxib-D4 is a deuterated form of Etoricoxib. Etoricoxib (T1574) is a synthetic non-steroidal anti-inflammatory compound, an orally available and selective COX-2 inhibitor with antipyretic, analgesic, and potential anticancer properties.

Etravirine (T2551) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. Etravirine-D4 is the deuterium labeled Etravirine.

Evogliptin tartrate has potential for anti-atherosclerosis therapy that targets arterial inflammation. Evogliptin tartrate is a potent, orally bioavailable and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, with antidiabetic activity.